LACTOLOGY FOUNDATION

Moxaverine (ATC A03AD30) is a papaverine derivative antispasmodic and phosphodiesterase inhibitor used mainly for functional gastrointestinal and circulatory disorders; lactation data are lacking, so use during breastfeeding should be cautious and individualized.medpedia.framar+4

Active substance and ATC class

Moxaverine is a synthetic isoquinoline derivative, structurally related to papaverine, classified in ATC group A03AD “Papaverine and derivatives”, code A03AD30. It belongs therapeutically to smooth‑muscle antispasmodics and exhibits additional hemorheologic and vasodilatory properties via phosphodiesterase inhibition.wikipedia+3

Indications and clinical use

Traditionally, moxaverine has been used for the treatment of functional gastrointestinal disorders with smooth‑muscle spasm such as irritable bowel–type abdominal cramping and intestinal colic. Beyond the A03 indication, the drug has been investigated parenterally in ophthalmology to improve ocular blood flow in conditions like age‑related macular degeneration and primary open‑angle glaucoma, reflecting its systemic vasodilator effects.drugbank+4

Mechanism of action and pharmacodynamics

Moxaverine acts as a direct smooth‑muscle relaxant and phosphodiesterase inhibitor, increasing intracellular cyclic nucleotides in vascular and visceral smooth muscle and thereby promoting vasodilation and spasmolysis. In clinical hemodynamic studies, systemic administration increased choroidal and optic nerve head blood flow and improved flow velocities in ophthalmic and posterior ciliary arteries, supporting a significant peripheral vasodilatory effect.pubmed.ncbi.nlm.nih+5

Pharmacokinetics (general considerations)

Published clinical pharmacokinetic data for moxaverine are sparse, and detailed parameters such as oral bioavailability, protein binding and half‑life are not well characterized in current open sources. Given its structural similarity to papaverine and classification as a systemic vasodilating antispasmodic, it is expected to undergo hepatic metabolism and biliary and/or renal excretion, but precise figures are not available and should not be extrapolated uncritically.pubchem.ncbi.nlm.nih+2

Adverse effects and toxicity profile

As a smooth‑muscle relaxant and vasodilator, moxaverine may cause adverse reactions related to hypotension and vascular dilation such as dizziness, headache, flushing and, rarely, syncope, especially after parenteral administration. Gastrointestinal side effects (nausea, abdominal discomfort), hypersensitivity reactions to the active substance or excipients, and potential exacerbation of pre‑existing severe hypotension or cardiac instability must also be considered in toxicological risk assessment.iovs.arvojournals+4

Contraindications and precautions

The drug is contraindicated in patients with known hypersensitivity to moxaverine or any component of the medicinal product, consistent with standard labeling for this class. Caution is advisable in patients with severe cardiovascular disease, marked hypotension or cerebrovascular compromise, where additional vasodilation could precipitate ischemia or syncope, and in those receiving other hypotensive or vasodilating agents due to potential additive effects.drugs.ncats+3

Overdose and poisoning considerations

Data on moxaverine overdose in humans are limited, but by analogy with papaverine derivatives and its pharmacology, large doses may provoke profound vasodilation, hypotension, reflex tachycardia, cardiac conduction disturbances, CNS symptoms (dizziness, confusion, possible seizures) and marked gastrointestinal atony. Management is supportive, focusing on airway protection, cardiovascular monitoring, treatment of hypotension with intravenous fluids and vasopressors as required, and symptomatic control of arrhythmias and seizures while considering potential drug interactions.wikipedia+2

Drug interactions and special populations

Because moxaverine is a vasodilating phosphodiesterase inhibitor, concomitant use with other vasodilators, antihypertensives or agents affecting cardiac conduction may enhance hypotensive or arrhythmogenic risk and warrants clinical vigilance. In elderly patients and those with compromised organ perfusion (such as ocular hypoperfusion syndromes), systemic hemodynamic responses may be accentuated, necessitating careful dose titration and monitoring.onlinelibrary.wiley+5

Use in pregnancy

There is insufficient controlled human data regarding moxaverine use in pregnancy, and its teratogenic potential has not been systematically evaluated in accessible literature. As with most non‑essential vasodilating antispasmodics, use during pregnancy should be restricted to situations where anticipated maternal benefit clearly outweighs potential fetal risks, with preference for better‑studied alternatives when available.msdmanuals+3

Use during lactation: evidence base

No specific human data describing moxaverine excretion into breast milk or its effects in breastfed infants were identified in current open references, and the drug is not listed in major publicly accessible breastfeeding medication overviews. Therefore, any lactation‑related assessment for moxaverine must be indirect, based on general principles of medicines in breastfeeding and on its pharmacologic class rather than empirical milk level or infant outcome studies.semanticscholar+6

Lactation risk assessment (theoretical)

General lactation guidance states that most medicines used at standard doses result in low relative infant doses, typically less than 10% of the weight‑adjusted maternal dose, and are considered compatible with breastfeeding, provided they lack inherent serious toxicity. For moxaverine, theoretical risk factors include systemic vasodilator effects and possible cardiovascular or CNS actions, but there is no evidence it belongs to recognized high‑risk groups such as cytotoxic agents, ergot alkaloids, lithium, or radioactive drugs which are clearly contraindicated in breastfeeding.medsafe+3

Practical recommendations in breastfeeding

In the absence of direct data, short‑term and low‑dose oral use of moxaverine in a healthy breastfeeding mother, with a term infant and no cardiac comorbidities, would likely produce low exposure and limited clinically significant risk, but careful individual assessment and informed consent are required. Where possible, clinicians should prefer antispasmodics and vasodilators with established lactation safety profiles, use the lowest effective dose for the shortest time, and monitor the infant for excessive sedation, feeding difficulties, irritability, or unusual cardiovascular symptoms.europeanjournalofmidwifery+3

Strategies to minimize infant exposure

General strategies applicable to moxaverine include timing breastfeeding sessions immediately before maternal dosing and allowing the longest possible interval between dose administration and the next feed, especially for immediate‑release formulations. For any prolonged or high‑dose therapy, or when treating vulnerable infants (premature, low birth weight, cardiac disease), consultation with a specialized medicines‑in‑lactation information service or use of an alternative with more robust lactation data is advisable.breastfeeding+2

Toxicological considerations in breastfed infants

If relevant amounts of moxaverine were to pass into human milk, potential infant effects by mechanism would include hypotonia, altered gastrointestinal motility (diarrhea or constipation), hypotension, and changes in alertness, although these remain theoretical in the absence of documented cases. Any suspected adverse reaction in a breastfed infant temporally related to maternal moxaverine therapy should prompt clinical evaluation, consideration of drug withdrawal or substitution, and reporting to pharmacovigilance systems.drugbank+5

Counseling points for healthcare professionals

When counseling breastfeeding patients, healthcare professionals should clearly explain that specific lactation data for moxaverine are lacking, and that recommendations rely on extrapolation from pharmacology and general breastfeeding‑medicine principles. Shared decision‑making should weigh the severity of the maternal condition, availability of better‑studied alternatives, maternal preference to continue breastfeeding, and the feasibility of infant monitoring or temporary interruption of breastfeeding if higher‑risk dosing regimens are required.msdmanuals+5